Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Rising Today

By Keith Speights – Aug 31, 2021 at 11:46AM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The vaccine stock is receiving a bump after the CDC issued updated guidance.

What happened

Shares of Novavax (NVAX 6.60%) were rising 2.8% as of 11:30 a.m. EDT on Tuesday after moving as much as 5% higher earlier in the day. The gains came after the U.S. Centers for Disease Control and Prevention (CDC) provided updated guidance that participants in Novavax's phase 3 clinical trial of its COVID-19 vaccine candidate who received two doses meet the criteria for being considered fully vaccinated.

So what

The CDC was clear that its updated guidance doesn't imply in any way that Novavax's vaccine, NVX-CoV2373, has been authorized by the Food and Drug Administration or has been recommended by the CDC or its Advisory Committee on Immunization Practices. With this in mind, nothing has materially changed for Novavax.

A healthcare professional giving a shot in the arm to a patient with another healthcare professional observing.

Image source: Getty Images.

However, the CDC's update is certainly helpful for anyone who participated in Novavax's late-stage U.S. study. It's also arguably a feather in Novavax's cap that the company was the only vaccine maker singled out in the CDC's guidance revision.

Now what

Novavax still expects to file for Emergency Use Authorization (EUA) in the U.K. in the third quarter of this year, with submissions in Europe, Canada, Australia, and New Zealand soon thereafter. Another big potential catalyst for the vaccine stock will come in the fourth quarter with Novavax's anticipated EUA filing in the U.S. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Novavax Stock Quote
$17.61 (6.60%) $1.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.